Site Editor

Thomas Flaig, MD

Advertisement
Advertisement

Long-Term Update on Treatment With Erdafitinib in Advanced Urothelial Carcinoma

By: Jenna Carter, PhD
Posted: Monday, February 7, 2022

Published in The Lancet Oncology are findings from the open-label phase II BLC2001 study, which examined the safety and efficacy of erdafitinib in the treatment of locally advanced or metastatic urothelial carcinoma. Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues assessed the long-term clinical outcomes with erdafitinib and found similar efficacy findings with their original trials. They also found that the 12-month median overall survival was 49% and the 24-month overall survival was 31%.

"Erdafitinib, a pan-fibroblast growth factor receptor tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma…,” stated Dr. Siefker-Radtke and colleagues. Based on these findings, the investigators think this agent should be investigated in other settings.

A total of 2,328 patients were screened across 126 medical centers in 14 different countries. A total of 212 were enrolled, and 101 were treated with erdafitinib. Patients were treated using an 8-mg/kg up titration regimen for 28 days. The primary endpoint was confirmed objective response rate, and the secondary endpoints were progression-free survival, overall survival, safety, response rate, and pharmacokinetics.

Findings revealed that 40% of patients (95% confidence interval [CI] = 30%–49%) achieved a confirmed investigator-assessed objective response, and this was consistent with the objective response rate at the time of the primary analysis. Among the responding patients, 36% had a partial response, and 4% had a complete response. Median progression-free survival was 5.5 months (95% CI = 4.3–6.0 months) for all 101 patients, and the 12-month progression-free survival rate was 21% (95% CI = 13%–29%). Median overall survival was 11.3 months (95% CI = 9.7–15.2 months), and the 12-month overall survival rate was 49% (95% CI = 39%–59%).

Disclosure: For full disclosure of the study authors visit www.thelancet.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.